FILTER
FILTERED INTERVIEW RESULTS
Dr. Trevor P. Castor
PRESIDENT & CEO, APHIOS
Aphios’ vision is to develop biotechnology products for improving health and treating chronic diseases in an environmentally sustainable manner.
Jay Shukla
PRESIDENT AND CEO, NIVAGEN PHARMACEUTICALS
Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and OTC products for the North American market.
Doug Giordano
SENIOR VP OF BUSINESS DEVELOPMENT, PFIZER
Pfizer outlines its plans to build its pipeline through partnerships as the company increasingly focuses on new science.
Michael Gladstone
PRINCIPAL, ATLAS VENTURE
Atlas Venture is an early-stage venture capital firm that invests in life sciences startup companies in the US.
David DeJean
SENIOR VICE PRESIDENT, SYSTECH INTERNATIONAL
Systech International is a technology leader in supply chain safety and brand protection.
Robert Foster
CEO, HEPION PHARMACEUTICALS
Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease.
Daniel J O’Connor
PRESIDENT & CEO, ONCOSEC MEDICAL INCORPORATED
OncoSec is a late-stage biotechnology company developing immunotherapy cancer treatments using its plasmid DNA delivery platform.
Peter Meath
MANAGING DIRECTOR & CO-HEAD OF HEALTHCARE AND LIFE SCIENCES, J.P. MORGAN COMMERCIAL BANKING
.P.Morgan explains the complete ecosystem that it has developed for life science companies, aiming to serve their needs throughout their entire life cycle, from opening a bank account on Day 1, to expanding internationally and through a potential IPO and beyond.
John Patrick Oroho
EXECUTIVE VICE PRESIDENT AND CHIEF STRATEGY OFFICER, PORZIO LIFE SCIENCES, LLC
Porzio Life Sciences, LLC (PorzioLS) is a provider of compliance operations products and services for the life sciences industry, and a wholly‐owned subsidiary of the Porzio, Bromberg & Newman, P.C. law firm.
Ciara Kennedy
PRESIDENT AND CEO, AMPLYX PHARMACEUTICALS
Amplyx Pharmaceuticals has a near-term focus on deadly fungal pathogens in vulnerable, immune-compromised patients.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Africa Energy 2024 - Pre-release
The pre-release edition of Africa Energy 2024 comprises analysis based on over 80 interviews with ministers and leading executives from IOCs, NOCs, independents, associations, investors and service providers, to provide an in-depth and holistic view of sub-Saharan Africa’s ever-evolving energy sector.
The pre-release edition of Africa Energy 2024 comprises analysis based on over 80 interviews with ministers and leading executives from IOCs, NOCs, independents, associations, investors and service providers, to provide an in-depth and holistic view of sub-Saharan Africa’s ever-evolving energy sector.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
